Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML Presented at the American Society of Hematology
BURLINGTON, Mass., Dec. 13, 2011 /PRNewswire/ -- Coronado Biosciences, Inc., (OTCBB: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that an oral presentation on CNDO-109 was given at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition held at the San Diego Convention Center in California. CNDO-109 is a biologic that activates natural killer (NK) cells for the treatment of acute myeloid leukemia (AML) and solid tumors.
Dr. Panagiotis Kottaridis of the Department of Haematology, Royal Free Hampstead NHS Trust and University College London Medical School, UK reported the final results of the Phase 1 clinical trial of CNDO-109 in AML (abstract #946). The results demonstrated that AML patients experienced a longer complete remission (CR) after receiving CNDO-109 activated NK cells than their previous CR.
The analysis was based on eight AML patients of whom five were in a subsequent CR, one was in their first CR, one was in partial relapse (PR) and one was in relapsing disease. As conditioning, patients received fludarabine 25mg/m2/day for three days plus a single fraction (2Gy) total body irradiation (TBI) on day four. 24 hours after the completion of TBI, patients received 1 million activated haploidentical related donor CNDO-109 tumor primed NK cells as a single i.v. infusion.
Three of the patients in a subsequent CR demonstrated a longer CR than their previous one, and the patient in PR reverted to CR. No comparison was available for the patient in their first CR, and the patient in relapsing disease was not evaluable.
No toxicity related to the infusion was observed. Seven patients experienced bone marrow suppression with a median time of 55 days (19-101) for neutrophil recovery.